Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. ("AMI"), a leading Israeli medical technology distributor, for the commercialization of GelrinC®, Regentis' proprietary implant for the repair of damaged knee cartilage, in Israel.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.